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Research
Exposure to fine particulate air pollution (PM) is 
associated with increased cardiovascular mortal-
ity and increased hospitalizations for myocardial 
infarction and congestive heart failure (Frampton 
and Utell 2000; Peters et al. 2000, 2004; Pope 
et al. 2004; Utell et al. 2002). Exposure to PM 
has been linked with increased risk for venous 
thrombosis (Pope 2009). Diabetes increases sus-
ceptibility to cardiovascular disease and further 
increases the cardiovascular risks associated with 
ambient PM exposure (Goldberg et al. 2006; 
Liao et al. 2005; Zanobetti and Schwartz 2002). 
Among 92 subjects with diabetes in the Boston 
area, O’Neill et al. (2005) found that exposure 
to ambient PM was associated with reduced 
vascular reactivity and with elevated blood 
markers of vascular inflammation and injury 
(O’Neill et al. 2007). Black carbon exposure 
showed the strongest associations, which sug-
gests that   carbon-containing PM from traffic or 
power plants were most important in causing 
vascular effects. Exposure to another marker of 
traffic (nitrogen dioxide) has also been related 
to incident diabetes among women (Brook 
et al. 2008).
Carbonaceous ultrafine particles (UFP; 
< 100 nm) emitted from diesel-powered motor 
vehicles and other combustion sources may 
contribute to the cardiovascular effects associ-
ated with PM exposure (Frampton and Utell 
2000). UFP deposit efficiently in the alveolar 
compartment of the lung (Chalupa et al. 2004; 
Daigle et al. 2003) and enter epithelial cells 
and the pulmonary vasculature (Geiser et al. 
2005) where they may perturb vascular func-
tion (Frampton et al. 2006; Shah et al. 2008), 
activate platelets (Radomski et al. 2005), and 
promote thrombus formation (Nemmar et al. 
2006). Panel studies of patients with coronary 
artery disease have shown relationships between 
UFP exposure and blood markers of platelet 
activation (Delfino et al. 2008; Rückerl et al. 
2007). In healthy volunteers, inhalation of die-
sel exhaust containing 350 µg/m3 PM increased 
blood thrombus formation in an ex vivo per-
fusion chamber and also increased formation 
of platelet-neutrophil and platelet-monocyte 
aggregates, which are markers of platelet acti-
vation (Lucking et al. 2008). However, these 
exposures contained both particulate and gas-
eous emissions at relatively high concentrations, 
so the causative agent or agents is unknown.
We have shown previously that inhalation 
of UFP consisting of elemental carbon, as sur-
rogates for UFP of combustion origin, subtly 
altered both pulmonary and systemic vascular 
function in healthy subjects (Frampton et al. 
2006, 2007; Shah et al. 2008). 
We hypothesized that inhalation of carbon 
UFP, without the gases and reactive organic 
molecules that are present in diesel exhaust, 
would activate vascular endothelium and 
blood platelets and promote coagulation in 
subjects with type 2 diabetes.
Materials and Methods
The Research Subjects Review Board of the 
University of Rochester approved the study. 
Informed, written consent was obtained from 
all subjects.
Subjects. Volunteers were 19 never-  smokers 
30–60 years of age with type 2 diabetes as   
defined by the World Health Organization 
(Alberti and Zimmet 1998). Subjects were 
recruited in Rochester, New York, using 
media advertisements; 38 persons were 
screened, and 19 of those screened met the 
study criteria and completed the study. We 
attempted to balance subject recruitment 
by sex and age (30–45 vs. 46–60 years old). 
Subjects were required to be on a stable medi-
cation regimen for at least 3 months prior 
to entry and were continued on the same 
regimen during the study. Exclusion crite-
ria included clinical cardiovascular disease, 
major organ dysfunction, uncontrolled hyper-
tension, frequent hypoglycemia, statin-type 
lipid-lowering medications (because of the 
anti-inflammatory effects of these medica-
tions), platelet-active drugs including aspirin, 
and occupational exposure to particles (e.g., 
welding, foundry work). Subjects were asked 
to avoid nonsteroidal antiinflammatory drugs 
and phosphodiesterase enzyme inhibitors dur-
ing the study and were questioned regarding 
compliance at each visit.
Protocol. This study was a double-blind, ran-
domized, crossover design in which each subject 
inhaled both filtered air (0–10   particles/cm3) 
and elemental carbon UFP (50 µg/m3, count 
median diameter of 32 nm) by mouthpiece 
for 2 hr at rest, with at least 3 weeks separat-
ing the exposures. Subjects were admitted to 
the University of Rochester General Clinical 
Research Center the evening prior to exposure 
and remained overnight. Baseline blood mea-
surements were performed at approximately 
0900 hours the following morning. The expo-
sures began at approximately 0930 hours. The 
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Ba c k g r o u n d: Diabetes confers an increased risk for cardiovascular effects of airborne particles.
oB j e c t i v e: We hypothesized that inhalation of elemental carbon ultrafine particles (UFP) would 
activate blood platelets and vascular endothelium in people with type 2 diabetes.
Me t h o d s : In a randomized, double-blind, crossover trial, 19 subjects with type 2 diabetes inhaled 
filtered air or 50 µg/m3 elemental carbon UFP (count median diameter, 32 nm) by mouthpiece 
for 2 hr at rest. We repeatedly measured markers of vascular activation, coagulation, and systemic 
inflammation before and after exposure. 
re s u l t s: Compared with air, particle exposure increased platelet expression of CD40 ligand 
(CD40L) and the number of platelet-leukocyte conjugates 3.5 hr after exposure. Soluble CD40L 
decreased with UFP exposure. Plasma von Willebrand factor increased immediately after exposure. 
There were no effects of particles on plasma tissue factor, coagulation factors VII or IX, or D-dimer.
co n c l u s i o n s: Inhalation of elemental carbon UFP for 2-hr transiently activated platelets, and pos-
sibly the vascular endothelium, in people with type 2 diabetes.
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first measurements occurred at 1200 hours 
(0.5 hr after completion of the exposure) and 
again at 1530 hours (3.5 hr after exposure). The 
subjects were then allowed to leave the center 
and returned the following 2 days for blood 
draws at 0900 hours (21 and 45 hr after the 
end of the   exposure).
Details of particle generation and char-
acterization have been published previously 
(Chalupa et al. 2002). The particles were 
generated in argon using an electric spark 
discharge between graphite electrodes in a 
commercial generator (Palas Aerosol Generator, 
model GFG-1000; Palas Co., Karlsruhe, 
Germany) modified to prevent off-gassing of 
organic materials from within the generator 
(McDonald et al. 2001). This produced par-
ticles consisting of > 95% elemental carbon, 
without metals. Particle number (condensa-
tion particle counters, Model 3220a; TSI, Inc., 
St. Paul, MN), mass (tapered element oscillat-
ing microbalance; Rupprecht and Patachnick, 
Albany, NY), and size distributions (Scanning 
Mobility Particle Sizer, Model 3071; TSI, Inc.) 
were monitored on both inspiratory and expi-
ratory sides of the subject. The subject inhaled 
from a mouthpiece and wore a nose clip.
Blood was drawn from an antecubital vein 
with minimal trauma, with the subject resting 
and in a supine position. Lipid profiles, hemo-
globin A1c (HgbA1c), microalbuminuria, and 
glucose were determined only at screening. 
Complete blood leukocyte and platelet counts 
were done at screening and all time points 
listed above. All were measured in the Strong 
Memorial Hospital Clinical Laboratories in 
Rochester, NY, using standard automated lab-
oratory methodology.
Immunocytometry. Immunofluorescence 
measurements were performed within 
1  hr  of  phlebotomy.  Antibodies  are 
listed in Supplemental Material, Table 1 
(doi:10.1289/ehp.1002237). Platelets were 
analyzed using a method adapted from Li 
et al. (1999) [see Supplemental Material, 
“Methods” (doi:10.1289/ehp.1002237)]. 
Circulating microparticles (MP) are cell frag-
ments < 1 µm released from cells in response 
to cell injury, activation, or apoptosis (Simak 
and Gelderman 2006). They may increase 
in conditions involving vascular injury or 
inflammation. MPs were identified using size 
gating and surface markers of the cells of ori-
gin [see Supplemental Material, “Methods” 
(doi:10.1289/ehp.1002237)].
Platelet-leukocyte conjugates were charac-
terized by gating the cellular region for simul-
taneous expression of leukocyte common 
antigen (CD45) and P-selectin (CD62P), 
an antigen expressed on activated platelets. 
Monocyte expression of surface markers was 
measured on a separately stained sample using 
light scatter and CD45 positivity, as described 
previously (Frampton et al. 2006). Flow 
analysis used CellQuest (BD Biosciences, 
San Jose, CA) and FloJo (TreeStar, Ashland, 
OR) software.
Plasma markers. Plasma was stored at 
–80°C for subsequent analyses of soluble mark-
ers, as previously described (Beckett et al. 2005). 
We used commercial enzyme-linked immuno-
assays (ELISA) for most [see Supplemental 
Material, Table 2 (doi:10.1289/ehp.1002237)] 
and customized ELISAs to measure plasma tis-
sue factor protein (sCD142) (Khorana et al. 
2008) and soluble CD40 ligand (CD40L) 
(Rückerl et al. 2007).
Data handling and statistics. This study 
used a standard, two-period crossover design 
in which each subject received both particles 
and air. The order of presentation was ran-
domized separately for each sex. A washout 
period of at least 3 weeks between the expo-
sures was included to minimize risk of car-
ryover effects, and testing for these effects was 
therefore not included in the models.
Our approach was based on the method 
described by Jones and Kenward (2003), using 
mixed models for the analysis of crossover tri-
als, with repeated measurements within treat-
ment (exposure) periods. There are two types 
of covariance patterns among measurements 
from the same subject: correlations among 
measurements in the same treatment period 
at different time points, and among measure-
ments from different treatment periods. We 
assumed that the between- and within-period 
treatment covariance structures were separable. 
To accommodate between-period treatment 
dependencies, we introduced subject effect in 
the mixed model. For the within-period treat-
ment dependencies, we assumed an unstruc-
tured correlation structure, an approach 
commonly used for repeated measurements. In 
this analysis, we used SAS, version 9, PROC 
MIXED (SAS Institute Inc., Cary, NC).
We ran two models: Model 1 examined 
the primary hypothesis of treatment (expo-
sure) effects and contained terms for treatment, 
period, time, and time-by-treatment inter-
actions; model 2 explored whether the exposure 
effects were different between men and women 
and between two age groups: 30–45 years old 
and 45–60 years old. Model 2 contained terms 
for treatment, sex, age group, treatment-by-sex 
interactions, and treatment-by-age interactions. 
To retain a parsimonious model given the sam-
ple size, n = 19, we did not include time in this 
model. Model 2 was considered exploratory, 
because the study was not adequately powered 
to test these interaction effects. Both models 
included adjustment for the corresponding 
baseline measurement prior to exposure in 
each period. The time variable in model 1 is a 
categorical variable, which models the overall 
response trend over time within each period, 
and the time-by-treatment interactions exam-
ine the treatment effects over time. We exam-
ined t-tests from the mixed-models output and 
assessed significance of contrasts of treatment 
effects at different time points. We used linear 
regression analysis to determine relationships 
between outcomes and subject characteristics. 
Significance was achieved by p < 0.05. Because 
multiple comparisons were involved and some 
end points were related, the congruence and 
plausibility of the results were considered in 
interpreting significance. Marginally statisti-
cally significant differences that were isolated, 
implausible, or inconsistent with other findings 
were not considered meaningful.
Results
Characteristics of the 19 subjects are found 
in Table 1. Sixty-nine percent (13/19) of the 
subjects were obese, with a body mass index 
(BMI) > 30 kg/m2. Triglycerides and the 
total cholesterol and high-density lipoprotein 
Table 1. Subject characteristics measured at screening.a
Age groups
Parameter Men Women 30–45 years 46–60 years
No. of subjects (n) 9 10 10 9
Age (years) 48.3 ± 8.8 43.7 ± 10.0 38.0 ± 1.4  54.7 ± 1.3
Race/ethnicity (n)
African American 0 3 2 1
Asian 1 0 0 1
Hispanic 0 1 0 1
White 8 6 8 6
BMI (kg/m2) 34.7 ± 5.2 31.1 ± 5.5 32.8 ± 2.1 32.8 ± 1.5
Cholesterol (mg/dL) 191.0 ± 36.7 168.5 ± 31.9 181.7 ± 11.9 176.3 ± 11.4
Triglycerides (mg/dL) 185.9 ± 55.1 102.9 ± 80.5* 142.6 ± 31.0 141.8 ± 20.1
High-density lipoprotein (mg/dL) 40.6 ± 7.0 47.5 ± 8.1 44.7 ± 2.5 43.7 ± 2.9
Low-density lipoprotein (mg/dL) 113.2 ± 38.0 100.5 ± 27.8 108.4 ± 12.1 104.4 ± 9.3
Cholesterol–high-density 4.8 ± 0.8 3.7 ± 0.9* 4.2 ± 0.3 4.2 ± 0.4
lipoprotein ratio
HgbA1c (mmol/mol) 7.6 ± 1.1 7.7 ± 1.8 7.6 ± 0.6 7.7 ± 0.4
Glucose (mg/dL) 151.4 ± 34.8 168.4 ± 94.0 174.7 ± 28.9 144.4 ± 12.3
Microalbuminuria (mg/dL) 20.2 ± 58.4 2.9 ± 5.9 18.6 ± 17.5 2.8 ± 2.1
(0.8 ± 0.5)b 1.0 ± 1.1c 1.1 ± 0.3b 0.7 ± 0.2c
aData are given as mean ± SD. bWithout one male outlier at 176.0 mg/dL. cWithout one female outlier at 19.3 mg/dL. 
*p < 0.05 between sexes.Stewart et al.
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ratios were significantly higher among the 
men. Diabetic control was variable, with the 
HgbA1c ranging from 5.6 to 11.0%, but only 
one subject was within the desirable range of 
< 6.0%. Two subjects had significant microal-
buminuria, only one of which was clinically 
significant, indicating early renal vascular 
injury. These subjects showed no marked dif-
ferences from the group mean UFP responses 
and were included in the final analysis. 
All subjects had normal renal function, as 
determined by serum creatinine level. Two 
subjects were on no medications. As treat-
ment for their diabetes, 12 subjects took oral 
agents, 2 took insulin, and 2 were on insu-
lin and an oral agent. Three subjects were on 
angiotensin-converting enzyme inhibitors and 
three were on β-receptor blockers.
The mean (± SD) UFP exposure param-
eters were as follows: target mass concentra-
tion 50 µg/m3, measured mass concentration 
50.7 ± 2.8 µg/m3, particle number concentra-
tion 10.0 ± 0.77 × 106 particles/cm3, particle 
count median diameter 31.6 ± 1.5 nm, geo-
metric SD 1.65 ± 0.01.
Subject queries revealed no exposure-  related 
symptoms and an inability to discriminate 
between the exposures. There were no signifi-
cant differences between exposures for the total 
white blood cell counts, leukocyte differential 
counts, or platelet counts (data not shown).
Model 1 analysis: effect of UFP exposure. 
Platelet activation was assessed by measur-
ing changes in platelet surface expression 
of CD40L and CD62P and changes in the 
number of platelet-leukocyte conjugates 
relative to the baseline values of each expo-
sure. Mean CD40L expression increased 
significantly 3.5 hr after exposure to UFP 
compared with air (Figure 1A), with a sig-
nificant UFP–time interaction, indicat-
ing the UFP effect on CD40L expression 
differed over time. CD40L expression 3.5 
hr after UFP was increased from baseline 
levels in 9 of the 13 subjects with complete 
data [see Supplemental Material, Figure 1 
(doi:10.1289/ehp.1002237)]. The increase in 
platelet expression of CD62P (Figure 1B) was 
not statistically significant (UFP–time inter-
action, p = 0.11), although the increases in 
CD62P 3.5 hr after UFP exposure (p = 0.09) 
correlated strongly by paired regression with 
those of CD40L (r = 0.94, p < 0.001). UFP 
exposure also significantly increased the num-
ber of leukocytes expressing CD62P, which 
indicates conjugation of leukocytes with acti-
vated platelets and/or platelet MP (Figure 1C). 
Detailed results for these surface markers are 
provided in Supplemental Material, Table 3 
(doi:10.1289/ehp.1002237).
Tissue factor, a measure of endothelial 
perturbation, was measured as expression on 
monocytes and platelets, as numbers of tis-
sue factor expressing MP, and as plasma pro-
tein [see Supplemental Material, Table 4 
(doi:10.1289/ehp.1002237)]. Although none 
showed statistically significant differences 
between UFP and air exposure, all increased, 
except the plasma levels, 3.5 hr after UFP 
exposure [see Supplemental Material, Figure 2 
(doi:10.1289/ehp.1002237)]. The plasma tis-
sue factor increased immediately after UFP 
exposure and then decreased. The increase in 
Figure 1. Markers expressed on the platelet surface 
with activation indicate differences in response to 
UFP relative to air. (A) Platelet expression of CD40L 
(n = 16) shows a significant UFP–time inter  action, 
with the greatest effect 3.5 hr after exposure 
(*t-test comparing UFP and air at 3.5 hr, correcting 
for baseline, p = 0.004). (B) Expression of CD62P 
(n = 19) shows a similar but nonsignificant increase 
at 3.5 hr. (C) The number of leukocytes expressing 
CD62P (n = 18), which is indicative of conjugation 
with activated platelets and/or platelet MP, shows 
a significant difference in response after UFP ver-
sus air exposure. Preexposure values are shown in 
the insets. Expression is measured in molecules of 
equivalent phycoerythrin (MEPE).
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platelet tissue factor expression 3.5 hr after 
UFP exposure (relative to baseline) approached 
significance [see Supplemental Material, 
Figure 2A (doi:10.1289/ehp.1002237)] 
(p = 0.07) and correlated strongly with the pre-
viously mentioned significant increases, at this 
time point, in expression of platelet CD40L 
(r = 0.91, p < 0.001). We found no significant 
effects of UFP exposure on the numbers of 
platelet or endothelial MPs [see Supplemental 
Material, Table 5 (doi:10.1289/ehp.1002237)].
We measured plasma concentrations of 
von Willebrand factor (vWF) (Figure 2A) as 
a marker of endothelial activation or injury. 
Mean vWF increased significantly 0.5 hr after 
UFP exposure compared with baseline levels 
(Figure 2A)—15 of 18 subjects with com-
plete data showed the increase 0.5 hr after 
UFP [see Supplemental Material, Figure 3 
(doi:10.1289/ehp.1002237)]. Plasma inter-
leukin-6 (IL-6) (Figure 2B) increased relative 
to baseline 3.5 hr after UFP exposure rela-
tive to baseline (t-test p = 0.09) but was not 
statistically significant (model 1 UFP effect, 
p = 0.13). Soluble CD40L decreased signifi-
cantly after UFP exposure (Figure 2C) (UFP 
effect, p = 0.021), a direction that was oppo-
site of what we expected. There were no signif-
icant UFP effects on soluble C-reactive protein 
(CRP) (Figure 2D), E-selectin, L-selectin, 
CD62P, intercellular cell adhesion molecule 
(ICAM-1), vascular cell adhesion molecule 
(VCAM-1), serum amyloid A (SAA), or the 
coagulation markers (D-dimer, Factors VII 
and IX) [see Supplemental Material, Table 6 
(doi:10.1289/ehp.1002237)].
Model 2 analysis: interactions of UFP expo-
sure with sex and age. A secondary objective 
of this study was to determine if subject sex 
and age influenced the effects of UFP. Three 
outcomes demonstrated significant UFP expo-
sure–sex interactions (Figure 3): the numbers of 
leukocytes and platelets expressing CD62P and 
those of MP expressing CD40L. For all three 
outcomes, men increased after UFP exposure 
relative to women. Only one variable showed 
a significant UFP–age interaction. The num-
ber of CD62P+ MP increased in subjects who 
were 45–65 years old but decreased in those 
who were 30–45 years old after UFP exposure 
(Figure 4B–C). This variable also showed an 
overall UFP exposure effect with the model 2 
analysis (Figure 4A), and a marginally signifi-
cant exposure–sex interaction (Figure 4D,E). 
Other variables showed no significant sex or 
age interactions, and overall, there did not 
appear to be convincing evidence for sex or age 
differences in UFP effects on platelet activation 
(data not shown).
We found no significant relationships 
between any of the significant UFP expo-
sure effects and BMI, total cholesterol, high- 
or low-density lipoprotein, HgbA1c, or 
  microalbuminuria.
Discussion
To our knowledge, this is the first clinical 
study of people with type 2 diabetes inhaling 
UFP. We found that inhalation of freshly gen-
erated elemental carbon UFP, when compared 
with filtered air, initiated several changes. 
Plasma vWF transiently increased 0.5 hr after 
exposure. Platelet expression of CD40L and 
the number of platelet-leukocyte conjugates 
increased 3.5 hr after exposure. On the other 
hand, soluble plasma CD40L decreased after 
exposure. There were significant sex interac-
tions in the UFP effects on platelet-leukocyte 
conjugates, CD62P+ platelets, and CD40L+ 
MP, but not for other end points. UFP expo-
sure increased the number of activated platelet 
MP in subjects 45–65 years old but decreased 
them in subjects 30–45 years old, the only 
significant age-related effect. These findings 
are consistent with effects of inhaled UFP on 
platelet activation.
The markers examined in this study reflect 
risk for atherosclerotic vascular disease. For 
example, increased plasma levels of vWF, which 
can be released by both vascular endothe-
lial cells and platelets, have been linked to 
endothelial dysfunction and increased cardio-
vascular disease risk (Lee et al. 2005; Roldán 
et al. 2005; Zareba et al. 2001). Both vWF 
and IL-6 are released into the plasma during 
acute coronary syndromes (Montalescot et al. 
1998) and are predictive of adverse outcomes 
(Lee et al. 2005). CD40L–CD40 interactions 
appear important in the pathogenesis of athero-
sclerosis (Phipps 2000). Surface expression of 
CD40L is considered a marker of platelet acti-
vation (Henn et al. 1998) and has been consid-
ered a marker of atherosclerotic vascular disease 
Figure 3. Sex-related responses. (A–B) Changes in the number of leukocytes expressing CD62P in men 
(A, n = 8) and women (B, n = 10). Model 2 analysis shows a significant overall UFP effect (p = 0.034) and 
a significant UFP–sex interaction. (C–D) Changes in the number of platelets expressing CD62P in men (C, 
n = 9) and women (D, n = 10). Model 2 analysis shows a significant UFP–sex interaction. (E–F) Changes 
in the number of MP expressing CD40L in men (E, n = 6) and women (F, n = 9). Model 2 analysis shows 
a significant UFP–sex interaction, with increases in men and decreases in women after UFP exposure. 
Preexposure values are shown in the insets.
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(Garlichs et al. 2001; Stumpf et al. 2003). 
Tissue factor appears to have an important role 
in mediating the increased thrombogenicity in 
persons with type 2 diabetes (Sambola et al. 
2003). Circulating MP that are thrombogenic 
often express tissue factor, and may enhance 
activation of platelets, leukocytes, and endothe-
lial cells (Jimenez et al. 2003; Morel et al. 
2006). Patients with acute coronary syndromes 
show increased levels of circulating platelet-
monocyte aggregates (Freedman and Loscalzo 
2002). Thus, the observed increases in vWF, 
platelet expression of CD40L, and platelet-leu-
kocyte conjugates are consistent with platelet 
activation in response to UFP exposure.
An increase in platelet expression of 
CD40L was detected 3.5 hr after UFP expo-
sure, yet soluble CD40L levels decreased, 
reaching a nadir 21 hr after exposure. The rea-
son for this inverse relationship is unknown. 
Some studies have associated increased 
soluble CD40L levels with cardiovascular dis-
ease (Garlichs et al. 2001; Schönbeck et al. 
2001), whereas others have not found such 
a relationship (Lim et al. 2004; Stumpf et al. 
2003). This may reflect the complex relation-
ships between platelet and plasma soluble 
CD40L that were reported by Mason et al. 
(2005). They found negative correlations 
between platelet surface and plasma soluble 
CD40L in patients with cardiovascular dis-
ease. Platelet CD40L, but not soluble CD40L, 
proved to be a reliable marker of platelet acti-
vation. In our study, it is possible that UFP 
exposure caused both an increase in platelet 
expression of CD40L and a more rapid clear-
ance of CD40L from the plasma. It is also 
possible that platelet activation does not always 
lead to release of CD40L into the plasma.
We compared the magnitude of the 
changes in platelet CD40L and plasma 
vWF observed in our study with previously 
published measurements in patients to under-
stand the potential risk of UFP effects in 
susceptible people. For platelet expression of 
CD40L, we observed a mean 13% increase 
[44 vs. 40 MEPE (molecules of equivalent 
phycoerythrin) units] 3.5 hr after UFP expo-
sure. Garlichs et al. (2001) found that platelet 
CD40L expression was 300% higher (11 vs. 
3.6 fluorescence intensity units, p < 0.001) 
in patients with unstable angina relative to 
patients with stable angina. Stumpf et al. 
(2003) found a 266% increase (35.6 vs. 13.4 
fluorescence intensity units, p < 0.001) in 
platelet CD40L expression in patients with 
ischemic cardiomyopathy compared with 
patients with coronary artery disease with-
out cardiomyopathy. For vWF, we observed a 
mean increase of 10% (138 vs. 125 percent-
age units) 0.5 hr after UFP exposure. Horii 
et al. (2008) found that vWF levels were 
40% higher (211 vs. 151 percentage units, 
p < 0.05) in elderly patients with acute myo-
cardial infarction than in age-matched healthy 
volunteers. Thus, the mean changes in CD40L 
expression and vWF in our study were smaller 
than, but within an order of magnitude of, the 
increases seen in patients with clinical cardio-
vascular disease.
Our findings add to previous observa-
tions in panel and clinical studies. In panel 
studies, exposure to ambient air pollution 
was associated with increased blood levels of 
vWF in patients with diabetes (O’Neill et al. 
2007). However, in patients with coronary 
artery disease, plasma CD40L was found to 
be increased, rather than decreased, in asso-
ciation with air pollution exposure (Rückerl 
et al. 2007). Panel studies have also shown 
pollutant-related increases in IL-6 and CRP 
(Delfino et al. 2008; Dubowsky et al. 2006) 
and reductions in platelet counts (Rückerl 
et al. 2007) and vascular endothelial function 
(O’Neill et al. 2005; Schneider et al. 2008). 
In clinical studies, inhalation of diesel engine 
exhaust caused vascular dysfunction (Mills 
et al. 2005; Peretz et al. 2008), increased 
platelet-  leukocyte aggregation (Lucking et al. 
2008), and increased cardiac ischemia during 
exercise in men with stable coronary artery dis-
ease (Mills et al. 2007). However, in another 
diesel inhalation study, Carlsten et al. (2007) 
did not find thrombogenic effects of diesel 
exhaust in healthy people.
Inhalation of concentrated ambient fine 
PM did not alter endothelial function or blood 
fibrinolytic function in patients with coro-
nary artery disease (Mills et al. 2008), possi-
bly because the PM concentrations were lower 
(190 µg/m3) than in the diesel studies and of 
largely nontraffic origin. Inhalation of concen-
trated ambient UFP increased plasma levels of 
D-dimer, a fibrin degradation product, indi-
cating increased formation and degradation 
of fibrin clot (Samet et al. 2009). However, 
Figure 4. Age-related responses. Change in the number of MP expressing CD62P for all subjects (A); sub-
jects 30–45 years old (B); subjects 46–60 years old (C); male subjects (D); and female subjects (E). Model 
2 analysis showed a significant overall UFP treatment effect and a significant UFP–age interaction. There 
was a marginally significant UFP–sex interaction. Preexposure values are shown in the insets.
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there were no effects on a variety of additional 
markers of coagulation and fibrinolysis that 
were measured in that study, and D-dimer lev-
els were unaffected in our study. In previous 
studies of healthy subjects in our laboratory 
(Pietropaoli et al. 2004), inhalation of elemen-
tal carbon UFP for 2 hr did not alter platelet 
counts or plasma levels of IL-6, vWF, fibrino-
gen, or factor VII. Inconsistent findings across 
these clinical studies may be related, in part, to 
differing subject populations, exposures, and 
measurement techniques.
Our current study extends previous studies 
in demonstrating that inhalation of elemen-
tal carbon UFP, at mass concentrations much 
lower than the diesel exhaust studies, induces 
platelet and possibly leukocyte and endothe-
lial activation in people with type 2 diabetes. 
The exposure mass concentration used in our 
study, 50 µg/m3, is relevant to concentrations 
encountered on or near roadways in urban 
environments, where the fine particle mass can 
exceed 100 µg/m3 (HEI Panel on the Health 
Effects of Traffic-Related Air Pollution 2010). 
The laboratory-generated particles used in 
our study did not contain metals or organic 
carbon, both of which have been implicated 
as components that drive PM health effects. 
Thus, additional mechanisms must be consid-
ered to explain the vascular effects of UFP, such 
as surface chemistry or direct translocation of 
particles to the vascular space.
Our study has limitations. The UFP gener-
ated in this study represent an imperfect sur-
rogate of ambient air UFP, and the observed 
effects therefore may not be representative of 
those occurring with exposures to ambient 
air pollution. Because ambient UFP contain 
organic carbon and other chemical species 
that may mediate toxicity, it is possible that 
the vascular effects of ambient UFP may be 
greater than for the elemental carbon UFP 
used in this study. The exposure concentra-
tions were considerably higher than ambient 
UFP concentrations, but were relevant to spe-
cific environments, such as on or near busy 
roads (Kittleson et al. 2004). Although sub-
jects were hospitalized overnight prior to each 
experimental exposure, it remains possible that 
uncontrolled environmental exposures, before 
and after the experimental exposures, affected 
their responses. However, influences of ambi-
ent exposures would likely have biased the 
results toward the null. We studied a relatively 
small number of persons with stable type 2 
diabetes in a specific age range, without clini-
cal cardiovascular disease, who were not on 
lipid-lowering statin drugs; our findings may 
not be representative of individuals with type 2 
diabetes in general, many of whom take statin-
type drugs. Furthermore, the study design does 
not allow us to determine whether diabetes or 
other subject characteristics confer increased 
susceptibility to the observed effects.
In summary, in people with type 2 diabe-
tes, inhalation of 50 µg/m3 elemental carbon 
UFP for 2 hr at rest caused transient activa-
tion of blood platelets, with possible associated 
activation of blood leukocytes and vascular 
endothelium. These effects, although transient 
and small in magnitude, suggest an acute vas-
cular insult with prothrombotic consequences 
that could increase the risk for an acute cardio-
vascular event in people with overt atheroscle-
rotic vascular disease. This may help explain 
the observed associations between PM expo-
sure and acute cardio  vascular effects in people 
with diabetes.
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